CD271: Roles in Immunology, Neural Crest Cells, and Beyond

CD271, formally known as the p75 neurotrophin receptor (p75NTR), is a cell-surface protein that defies tidy categorization. Originally discovered as a receptor for nerve growth factor, it has since turned up in contexts that stretch far beyond the nervous system, from sorting stem cells in bone marrow to driving the invasive behavior of brain tumors. Its versatility comes from an unusual ability to switch between promoting cell survival and triggering cell death depending on which molecular partners it teams up with, making it one of the more unpredictable and intensely studied receptors in modern biology.

How CD271 Works at the Cell Surface

CD271 belongs to the tumor necrosis factor receptor superfamily, a group of proteins known for regulating whether cells live, die, or change their identity. Its primary job is to bind neurotrophins, a family of signaling molecules that guide the development and maintenance of neurons. These include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3). Crystal structure work has revealed that when NT-3 binds to the receptor’s outer domain, the two form a symmetrical complex: a pair of NT-3 molecules surrounded by two CD271 molecules, creating a 2:2 cluster at the cell surface. Earlier structural studies had suggested a lopsided 2:1 arrangement, but that turned out to be an artifact caused by stripping sugar molecules off the receptor during sample preparation.¹

What makes CD271 so interesting, and so tricky to study, is that its behavior flips depending on context. Mature neurotrophins generally push cells toward survival and growth. But cells also produce immature versions of these molecules, called pro-neurotrophins, and when pro-neurotrophins bind CD271 in partnership with another receptor called sortilin, the outcome reverses: the cell gets a death signal. Researchers have mapped the contact points between sortilin and CD271 and found that their outer domains need to physically touch for the death-promoting complex to form. The intracellular portion of sortilin then regulates how fast CD271 gets chopped up by enzymes embedded in the cell membrane, a cleavage step that is required for the death signal to go through.² This dual personality, survival or death depending on the ligand and the co-receptor, runs through virtually every biological role CD271 plays.

A Neural Crest Legacy

CD271 earned its earliest reputation in developmental biology. During embryonic development, a transient population of cells called neural crest cells migrates away from the forming nervous system and disperses throughout the body, eventually giving rise to peripheral neurons, pigment-producing melanocytes, smooth muscle in blood vessels, and parts of the skull and face. CD271 is one of the most reliable markers of these migratory progenitors. Its expression identifies cells that still retain multipotency, the ability to differentiate into several distinct cell types, and it appears to help regulate the plasticity that neural crest cells need as they encounter different tissue environments and commit to specific fates.

This developmental role has deep evolutionary roots. Comparative studies of the receptor across vertebrate species show that CD271 sequences in cartilaginous fish such as the small-spotted catshark sit at the base of the vertebrate family tree, consistent with the known evolutionary relationships among these groups.³ The receptor’s structure and function have been conserved for hundreds of millions of years, which suggests that whatever it does for neural crest cells and neurons, it is too important to lose. This ancient heritage also means that findings about CD271 in laboratory mice or zebrafish tend to be relevant to human biology, because the core signaling machinery has changed remarkably little over evolutionary time.

Sorting Stem Cells in the Bone Marrow

One of the most practically useful things about CD271 is that it marks a specific type of adult stem cell. Mesenchymal stem cells (MSCs) are the cells in bone marrow, fat tissue, and other organs that can turn into bone, cartilage, or fat cells. They are also potent regulators of the immune system. The problem is that MSCs are rare, making up a tiny fraction of the cells in a marrow sample, and they are traditionally identified by their tendency to stick to plastic dishes in the lab and expand. That approach works, but it is slow and can alter the cells’ properties.

CD271 has emerged as the most specific surface marker for picking MSCs out of a mixed bone marrow sample before any lab culture takes place. It is expressed on these cells more consistently than other markers, and when researchers use it to sort cells, the resulting CD271-positive population reliably differentiates into bone, fat, and cartilage lineages. For bone marrow and fat tissue in particular, CD271 is considered a highly suitable selection tool.⁴ The cells isolated this way also produce significantly higher levels of signaling molecules compared to MSCs obtained by conventional plastic-adherence methods, and they strongly suppress the proliferation of immune T cells in laboratory assays. Most of that immunosuppressive effect is mediated by prostaglandin E2 rather than nitric oxide.⁵

When researchers compared CD271-positive and CD271-negative MSCs from human fat tissue, the CD271-positive cells expressed angiogenic genes at higher levels and inflammatory genes at lower levels. They were also more likely to carry the full complement of standard stem cell surface markers and to promote the growth of new blood vessels.⁶ This combination of traits, immunosuppressive, pro-vascular, and enriched for genuine stem cell character, has made CD271-selected MSCs attractive candidates for regenerative medicine, a point we will return to later.

CD271 and the Immune System

CD271’s immune-related roles extend well beyond marking MSCs. The receptor turns up on dendritic cells, which are the sentinels of the immune system responsible for presenting foreign material to T cells, and on myeloid-derived suppressor cells, a population known for dampening immune responses. Its expression on these cell types suggests a direct role in regulating how the immune system escalates or de-escalates its activity.⁷

The connection runs deeper than receptor expression alone. NGF, the ligand that first defined CD271, is elevated in numerous inflammatory and autoimmune conditions including multiple sclerosis, chronic arthritis, and systemic lupus erythematosus. Mast cells, the immune cells best known for their role in allergic reactions, both produce NGF and respond to it. In conditions where mast cell numbers are abnormally high, NGF appears to fuel a feedback loop between the nervous system and the immune system, potentially driving tissue inflammation into a self-reinforcing cycle.⁸ This neuroimmune crosstalk is one of the reasons CD271 keeps appearing in studies of diseases that do not seem, at first glance, to have anything to do with the nervous system. Wherever NGF and its receptors are active, the boundary between “neural” and “immune” is blurry at best.

Cancer Stem Cells and Treatment Resistance

The same plasticity that makes CD271 valuable in development becomes dangerous when it is hijacked by cancer. Across several tumor types, CD271 marks a subpopulation of cells with enhanced stem-like properties, greater capacity for self-renewal, and resistance to chemotherapy.

In melanoma, the most lethal form of skin cancer, a small minority of cells that are positive for both CD24 and CD271 display hybrid characteristics that combine the traits of cells carrying just one marker. This double-positive population shows heightened ability to form spheres in culture (a proxy for self-renewal), greater migratory and invasive capacity, and stronger resistance to targeted drug therapy compared to cells positive for either marker alone.⁹ The connection to neural crest biology is more than superficial here. Melanocytes are neural crest derivatives, and the molecular programs that allow normal melanocyte precursors to migrate during development appear to be reactivated in melanoma cells that spread to distant organs. CD271 sits at the intersection of these developmental and oncogenic programs, a point explored in perspective work on melanoma phenotype switching and tumor initiation.¹⁰

The pattern is not limited to melanoma. In glioma, the most common primary brain cancer, an unbiased screen for genes driving invasive behavior identified CD271 as a central regulator of tumor invasion. The receptor is expressed and functional in two of the most clinically devastating compartments of glioma: the highly infiltrative cells that escape surgical removal, and the treatment-resistant brain tumor-initiating cells sometimes called brain tumor stem cells.¹¹ Meanwhile, broader surveys across cancer types have found that CD271-positive cancer cells consistently show higher sphere-forming and colony-forming ability, elevated expression of stemness-related genes, and resistance to standard chemotherapy compared to their CD271-negative counterparts. Epigenetic mechanisms, chemical modifications to DNA or its packaging proteins that switch genes on or off without altering the underlying sequence, appear to regulate how much CD271 a cancer cell expresses.¹²

The clinical implication is sobering. Standard chemotherapy tends to kill the bulk of a tumor while leaving CD271-positive stem-like cells behind. Those surviving cells can then regenerate the tumor, potentially in a more aggressive form. Understanding what controls CD271 expression in these cells, and finding ways to target them, is an active area of research.

Liver Repair and the Resolution of Fibrosis

CD271’s involvement in tissue repair offers a very different angle on the same survival-versus-death signaling. When the liver is injured chronically, whether by alcohol, viral hepatitis, or metabolic disease, specialized cells called hepatic stellate cells activate and transform into myofibroblasts, the scar-producing cells responsible for fibrosis. These myofibroblasts express both CD271 and sortilin, the co-receptor pair that determines whether neurotrophins promote survival or death.

Research using human liver myofibroblasts found that mature NGF pushes them toward death, while the immature pro-NGF form protects them from dying. During recovery from experimental liver fibrosis in rodents, pro-NGF levels drop, and the decline tracks with loss of myofibroblasts by programmed cell death. In mice engineered to lack CD271’s ligand-binding domain, the resolution of fibrosis was significantly slowed and myofibroblast clearance was impaired.¹³ A separate study confirmed that CD271 is expressed in human stellate cells during fibrotic and cirrhotic liver injury and functions as a regulator of liver repair.¹⁴

The practical significance is that CD271-mediated signaling appears to be one of the switches that determines whether liver scarring reverses or persists. If the balance tips toward pro-NGF and myofibroblast survival, fibrosis stays. If mature NGF dominates and CD271 promotes apoptosis, the scar-producing cells die off and the liver architecture can recover. Manipulating this balance pharmacologically is an intriguing, though still early-stage, therapeutic idea for chronic liver disease.

A Potential Biomarker for Neurodegenerative Disease

When CD271 gets cleaved at the cell surface, its outer portion, called the extracellular domain (ECD), is released into body fluids. Researchers have found elevated levels of this shed fragment in people with several neurodegenerative conditions, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), age-related dementia, schizophrenia, and diabetic neuropathy.¹⁵ Whether this fragment can serve as a reliable diagnostic or prognostic biomarker remains an open question, but some of the early results are striking.

In ALS specifically, urinary levels of the CD271 extracellular domain were about three times higher in patients than in healthy controls. The difference distinguished ALS from healthy controls with 100% specificity and 93% sensitivity, and from people with other neurological conditions such as Parkinson’s disease and multiple sclerosis with 79% specificity and 93% sensitivity.¹⁶ ALS is notoriously difficult to diagnose quickly because it mimics other conditions and requires ruling out many alternatives; a simple urine test that performs this well would be a significant advance if the findings hold in larger studies. The numbers in that initial study were small, with only 28 ALS patients and 12 controls, so replication in bigger and more diverse cohorts is needed before drawing firm conclusions about clinical utility.

Therapeutic Approaches Targeting CD271

The sheer range of diseases connected to CD271 has naturally attracted drug developers. Two broad strategies are in play: using small molecules to modulate the receptor’s signaling, and using CD271 as a sorting handle to isolate stem cells for transplantation.

On the drug side, researchers have designed non-peptide small molecules modeled on a loop of the NGF protein. These compounds bind to CD271, promote cell survival, and block the death signal triggered by pro-NGF. The goal is to develop agents with high potency and specificity that could treat neurodegenerative diseases, traumatic nerve injury, and other conditions where unwanted cell death is driven by CD271 signaling.¹⁷ One of the most advanced of these compounds, known as LM11A-31, has shown promise in models of tauopathy, the protein aggregation that underlies Alzheimer’s disease and related dementias. LM11A-31 dampens degenerative signaling through CD271 and boosts pathways that maintain the structure of dendritic spines, the tiny protrusions on neurons where most synaptic communication happens.¹⁸

On the stem cell side, clinical-grade magnetic beads coated with antibodies against CD271 have been tested for purifying MSCs from bone marrow for therapeutic use, particularly bone regeneration. Researchers compared different starting materials and found that the best combination of cell purity and yield came from using bone marrow filtrate harvested during hip surgery. The selected cells retained all the expected MSC characteristics, confirming that the enrichment process does not strip the cells of their functional properties.¹⁹ A protocol that can rapidly pull high-quality, uncultured stem cells out of surgical waste material would simplify and speed up procedures like grafting bone in orthopedic or dental surgery.

Why One Receptor Keeps Turning Up Everywhere

A recurring question in CD271 research is why a single receptor matters in so many seemingly unrelated settings, from embryonic neural crest migration to adult liver scarring to tumor invasion. Part of the answer lies in the receptor’s modular design. CD271 does not have strong signaling capacity on its own. Instead, it partners with different co-receptors, Trk family receptors for survival signaling, sortilin for death signaling, and possibly others not yet fully characterized, to produce context-specific outcomes. The receptor essentially acts as a platform whose output depends on which other molecules are nearby. In a developing neuron surrounded by Trk receptors and mature NGF, the result is growth and survival. In a fibrotic liver where pro-NGF levels are high and sortilin is present, the result is a tug-of-war between scar-cell survival and scar-cell death. In a melanoma cell that has reactivated embryonic migration programs, the result is enhanced invasiveness.

The other part of the answer is evolutionary. As the phylogenetic data from cartilaginous fish confirm, this receptor has been conserved across the entire vertebrate lineage.³ When evolution holds onto a gene that tightly, it usually means the gene was co-opted for multiple essential functions over time. Neural crest regulation likely came first, but as vertebrate bodies became more complex, the same receptor was repurposed for immune modulation, tissue repair, and stem cell maintenance. Each new role did not require a new gene, just a new cellular context in which existing signaling logic could produce a useful outcome. That deep conservation is also why CD271 keeps appearing as a marker and a drug target across so many branches of medicine: it is not a peripheral player borrowed by each system independently, but a core piece of signaling hardware that vertebrate biology has built on again and again.